Today In MarCom: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today In MarCom.

Press releases published on October 28, 2026

Oct. 28, 2026

ABM Announces Executive Leadership Changes

Indeterminate GlobeNewswire

Oct. 28, 2026

Hudson Technologies Reports Third Quarter 2026 Results

Indeterminate GlobeNewswire

Oct. 28, 2026

Fortinet Reports Strong Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Oct. 28, 2026

Churchill Downs Incorporated Reports 2026 Third Quarter Results

Indeterminate GlobeNewswire

Oct. 28, 2026

TFI International Adjusts Timing of 2026 Third Quarter Webcast

Indeterminate GlobeNewswire

Oct. 28, 2026

TFI International modifie l’horaire de la webdiffusion du troisième trimestre de 2026

Indeterminate GlobeNewswire

Oct. 28, 2026

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

Indeterminate GlobeNewswire

Oct. 28, 2026

Adamas Trust, Inc. Reports Third Quarter 2026 Results, Maintains Focus on Disciplined Portfolio Management

Indeterminate GlobeNewswire

Oct. 28, 2026

Latham Group, Inc. to Participate at Conferences in November and December 2026

Indeterminate GlobeNewswire

Oct. 28, 2026

Churchill Downs Incorporated Announces New $750 Million Share Repurchase Program

Indeterminate GlobeNewswire

Oct. 28, 2026

MIMEDX Announces Third Quarter 2026 Operating & Financial Results

Indeterminate GlobeNewswire

Oct. 28, 2026

Churchill Downs Incorporated Appoints Michael Tucker to Board of Directors

Indeterminate GlobeNewswire

Oct. 28, 2026

NewtekOne, Inc. Reports 3Q26 Basic and Diluted EPS of $0.34

Indeterminate GlobeNewswire

Oct. 28, 2026

Churchill Downs Incorporated Receives Local Approvals for New HRM Entertainment Venue in Henry County, Virginia

Indeterminate GlobeNewswire

Oct. 28, 2026

Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis

Indeterminate GlobeNewswire

Oct. 28, 2026

ARS Pharma to Report Third Quarter 2026 Financial Results

Indeterminate GlobeNewswire

Oct. 28, 2026

Kymera Therapeutics to Announce KT-579 Phase 1 Healthy Volunteer Trial Results on October 29, 2026

Indeterminate GlobeNewswire

Oct. 28, 2026

MIMEDX Announces $25 Million Patent License Agreement

Indeterminate GlobeNewswire

Oct. 28, 2026

SPACCircle Acquisition Corp. Completes $100 Million Initial Public Offering

Indeterminate GlobeNewswire

Oct. 28, 2026

FormFactor, Inc. Reports 2026 Third Quarter Results

Indeterminate GlobeNewswire